In a Phase I clinical trial, the administration of enadenotucirev as a monotherapy resulted in the infiltration of CD8+ T cells within microsatellite stable (MSS) colorectal cancer (CRC) tumors, indicating the potential for virus-induced immunogenicity (10). This evidence concerns the gene CD8A and colorectal carcinoma.